Akut mieloid leukémia (AML): vizsgálatok itt: Kanada
23 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleTesting New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Where
- Calgary, Edmonton, Greenfield Park, Halifax, Montreal, Ottawa, Toronto, Winnipeg
- Életkor
- 18 év to 59 év
- People
- 335 worldwide
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT05554406 - 2. fázisTaking peopleVenetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Where
- Montreal
- Életkor
- 18 év and over
- People
- 147 worldwide
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT06317649 - 3. fázisTaking peopleA Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Where
- Calgary, Halifax, Hamilton, London, Montreal, Toronto, Vancouver, Winnipeg
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00 - 2. fázisTaking peopleMYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Where
- Calgary, Edmonton, Greenfield Park, Halifax, Hamilton, Montreal, Ottawa, Toronto, Winnipeg
- Életkor
- 18 év and over
- People
- 2000 worldwide
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT05564390 - 2. fázisTaking peopleComparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Where
- Calgary, Edmonton, Greenfield Park, Halifax, Hamilton, Montreal, Toronto, Winnipeg
- Életkor
- 18 év to 59 év
- People
- 153 worldwide
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT05554393 - 1/2. fázisTaking peopleStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Where
- Montreal, Toronto
- Életkor
- 16 év and over
- People
- 85 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00 - 3. fázisTaking peopleStudy of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Where
- London, Montreal, Toronto
- Életkor
- 12 év and over
- People
- 468 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00 - 3. fázisTaking peopleStudies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Where
- Montreal, Vancouver
- Életkor
- 18 év and over
- People
- 1300 worldwide
- Run by
- Kura Oncology, Inc.
See details and how to joinNCT07007312 · EU 2025-521314-25-00 - 1/2. fázisTaking peopleA Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Where
- Toronto
- Életkor
- 30 nap and over
- People
- 447 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00 - 1. fázisTaking peopleZiftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
- Where
- Toronto
- Életkor
- 0 év to 21 év
- People
- 20 worldwide
- Run by
- PedAL BCU, LLC
See details and how to joinNCT06376162 · EU 2023-505262-28-00 - 2/3. fázisTaking peopleA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Where
- St. John's, Toronto
- Életkor
- 18 év and over
- People
- 316 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00 - 2. fázisNot yet taking people in KanadaGilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia
- Where
- Vancouver
- Életkor
- 18 év and over
- People
- 20
- Run by
- Florian Kuchenbauer
See details and how to joinNCT07755202 - 3. fázisTaking peopleA Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Where
- Calgary, Edmonton, Halifax, Hamilton, Kingston, London, Montreal, Ottawa, Québec, Saskatoon, Sherbrooke, Toronto, Vancouver, Winnipeg
- Életkor
- 6 hónap to 21 év
- People
- 1400 worldwide
- Run by
- Children's Oncology Group
See details and how to joinNCT04293562 - 2. fázisTaking people(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Where
- Edmonton, Toronto
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00 - 1/2. fázisTaking peopleThe Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Where
- Calgary, Edmonton, Halifax, London, Montreal, Ottawa, Québec, Sherbrooke, Toronto, Vancouver, Winnipeg
- Életkor
- Up to 22 év
- People
- 960 worldwide
- Run by
- PedAL BCU, LLC
See details and how to joinNCT04726241 - No phaseTaking peopleA Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
- Where
- London
- Életkor
- 6 év to 39 év
- People
- 330 worldwide
- Run by
- Children's Oncology Group
See details and how to joinNCT05702645 - 2. fázisCsak meghívásosA Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
- Where
- Edmonton, Nova Scotia, Ottawa, Toronto
- Életkor
- 18 év and over
- People
- 332 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01 - 2. fázisNot yet taking people in KanadaEvaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)
- Where
- Winnipeg
- Életkor
- 18 év and over
- People
- 75
- Run by
- University of Manitoba
See details and how to joinNCT07528417 - 2. fázisTaking peopleEvaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
- Where
- Winnipeg
- Életkor
- 18 év and over
- People
- 75
- Run by
- University of Manitoba
See details and how to joinNCT06599762 - 1. fázisNot yet taking people in KanadaPhase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma
- Where
- Montreal, Toronto
- Életkor
- 2 év to 12 év
- People
- 12
- Run by
- Michel Duval
See details and how to joinNCT07518654 - 1/2. fázisTaking peopleA Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Where
- Calgary, Edmonton
- Életkor
- 12 év and over
- People
- 606 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555 - No phaseTaking peopleEvaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy
- Where
- Toronto
- People
- 45
- Run by
- University Health Network, Toronto
See details and how to joinNCT06510868 - 1. fázisTaking peopleStudy of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Where
- Toronto
- Életkor
- 18 év and over
- People
- 242 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT04260022